The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

The National Institute for Health and Care Excellence (NICE) has maintained its decision not to recommend two treatments for Alzheimer’s disease on the NHS, after concluding that they still do not ...

The benefits from 2 new Alzheimer’s treatments remain too small to justify the additional cost to the NHS, an independent NICE c ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...